Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing

Launched by SOUTHWEST HOSPITAL, CHINA · Nov 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for oral chronic graft-versus-host disease (cGVHD), which can occur in patients who have received a stem cell transplant. cGVHD happens when the donor's immune cells attack the recipient's body, particularly affecting the mouth and causing painful symptoms like ulcers and redness. The trial is testing a special dressing made from human umbilical cord mesenchymal stem cells (MSCs) to see if it can help reduce these symptoms and improve patients' quality of life.

To join the trial, participants must be under 65 years old, in relatively good health, and have stable blood counts after their transplant. Those with severe organ dysfunction or other serious health issues won't be eligible. Participants can expect to receive the MSC dressing and will be closely monitored throughout the study. This trial aims to provide a new, effective, and less complicated treatment option for managing oral cGVHD, especially since current treatments can lead to other complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. No gender limitation, age \<65 years old; KPS score \>60, estimated survival \>3 months.
• • 2. No serious damage to the function of major organs of the whole body.
• • 3. Donor hematopoietic reconstruction was stable (neutrophils \>0.5×10\^9/L, platelets \>20×10\^9/L).
• • 4. Stable control of primary blood diseases.
• • 5. Voluntary examination, informed consent.
• Exclusion Criteria:
• • 1. Have severe heart, kidney or liver dysfunction.
• • 2. Those combined with other malignant tumors need treatment.
• • 3. There are clinical symptoms of brain dysfunction or severe mental illness and the inability to understand or follow the research protocot4. Patients who cannot be guaranteed to complete the necessary treatment plan and follow-up observation.
• • 5. Patients with severe acute allergic reactions. 6. Clinically uncontrolled active infection. 7. Patients who are participating in other clinical trials. 8. Researchers believe that the subject is not suitable for clinical trials for other reasons.